Trials / Terminated
TerminatedNCT03809039
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects
A Randomised, Double-Blind, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of MT-6345 in Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Tanabe Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-6345 | MT-6345 |
| DRUG | MT-6345 Placebo | MT-6345 Placebo |
Timeline
- Start date
- 2019-01-15
- Primary completion
- 2019-07-01
- Completion
- 2020-07-01
- First posted
- 2019-01-18
- Last updated
- 2025-12-31
- Results posted
- 2021-09-21
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03809039. Inclusion in this directory is not an endorsement.